MedTrace Logo

Personalized Cancer Vaccine in Egyptian Cancer Patients

NCT05059821 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-08-11

No results posted yet for this study

Summary

Evaluate safety and immunogenicity of peptide cancer vaccine in patients with hepatocellular carcinoma (HCC) who developed recurrence after surgical resection and refractory to the available institutional standard of care lines of treatment .

Conditions

Interventions

BIOLOGICAL

Peptide cancer vaccine

Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months

Sponsors & Collaborators

  • zeinab ahmed yousif hasan ashour

    lead OTHER

Principal Investigators

  • Zeinab A Ashour, MD · Ain Shams University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-19
Primary Completion
2024-04-30
Completion
2024-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059821 on ClinicalTrials.gov